A Phase 1 interventional study of capecitabine and oxaliplatin in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-14.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing oxaliplatin in Stomach Neoplasms — 18 open to participants now, 23 under way, 6 of them phase 3. Oxaliplatin · Stomach Neoplasms.
Among the 131 studies testing oxaliplatin in Stomach Neoplasms, this one is the 47th largest by enrollment of the 129 interventional ones that give a count, is one of 6 that started in 2008, is one of 15 in phase 1, and was the 30th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →18 of the 131 studies testing oxaliplatin in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18–80
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 19+
Ukrainian Society of Clinical Oncology · Sites in Lithuania, Ukraine
Ages 18–80
RemeGen Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 89 · Phase 3 24 · Phase 4 3
First in 1998; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 51 across the 129 interventional studies. Of the 74 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 131 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
27 studies in Stomach Neoplasms by Pfizer: 5 open now, 7 under way, 1 of them phase 3. Of 20 finished, 10 (50%) have results posted.
Among the 27 studies in Stomach Neoplasms by Pfizer, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2008, is one of 18 in phase 1, and was the 5th registered.
Pfizer’s Stomach Neoplasms studies by the year they started, since 2002.
4 of the studies testing oxaliplatin in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06028737Phase 3Ukrainian Society of Clinical OncologyTotal Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer | 2027-04-25 |
| NCT07257575Guangdong Provincial People's HospitalA Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | 2027-01-31 |
| NCT05184803Asan Medical CenterA Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer | 2027-06-30 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies testing oxaliplatin in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 27 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the safe and tolerable doses of sunitinib given together with either cisplatin and capecitabine or oxaliplatin and capecitabine in patients who have advanced gastric cancer who have not received prior chemotherapy for their advanced cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: capecitabine · Drug: oxaliplatin · Drug: sunitinib malate
Drug: capecitabine · Drug: cisplatin · Drug: sunitinib malate
Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Oxaliplatin is given 110mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Also known as: Sutent
Capecitabine is given orally at 1000mg/m\^2 twice a day for 14 days followed by 7 days of drug free period.
Cisplatin is given 80mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)
Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having \>3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery \>14 days.
Time frame: Baseline up to Day 21
Maximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)
Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Cmax of CAP
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmax of 5-fluorouracil (Metabolite of CAP, 5-FU)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Minimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)
Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Cmin of CAP
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmin of 5'DFCR
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmin of 5'DFUR
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Cmin of 5-FU
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Time to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)
Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Tmax for CAP
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Tmax for 5'DFCR
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Tmax for 5'DFUR
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Tmax for 5-FU
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Terminal Elimination Half-Life (t1/2) for SU, SU012662, and Total Drug (SU + SU012662)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
t1/2 for CAP
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
t1/2 for 5'DFCR
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
t1/2 for 5'DFUR
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
t1/2 for 5-FU
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Area Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state.
Time frame: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Area Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU
AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12)
Time frame: Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
AUClast for 5'DFCR
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
AUClast for 5'DFUR
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
AUClast for 5-FU
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)
Percentage of Participants With Objective Response
Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline, Day 21 of every even-numbered cycle up to 15 months
Duration of Response (DR)
DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first.
Time frame: Baseline up to Month 15
Progression-Free Survival (PFS)
PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
Time frame: Baseline up to Month 15
| Milestone | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| Started | 6 | 7 | 15 | 23 | 3 | 22 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 7 | 15 | 23 | 3 | 22 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 5 | 0 | 1 |
| Withdrew: Objective progression or relapse | 6 | 5 | 12 | 17 | 3 | 16 |
| Withdrew: Participant refused treatment | 0 | 1 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 | 3 |
Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having \>3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery \>14 days.
| participants | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| Number of Participants With First-cycle Dose Limiting Toxicities (DLTs) | 1 | 0 | 3 | 2 | 2 | 0 |
| nanograms per milliliter (ng/mL) | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cmax SU011248 | 40.1 ± 10.8 | 69.7 ± 17.6 | 46.5 ± 10.8 |
| Cmax SU012662 | 14.0 ± 11.3 | 23.7 ± 9.9 | 16.6 ± 3.3 |
| Cmax total drug (SU011248+SU012662) | 53.9 ± 22.1 | 93.0 ± 24.9 | 62.4 ± 13.4 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 7000 ± 7354 | 2051 ± 1109 | 11681 ± 8034 |
| Cycle 1, Day 14 | 20491 ± 27098 | 1989 ± 1686 | 16276 ± 15832 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4800 ± 863 | 3352 ± 1255 | 8017 ± 3692 |
| Cycle 1, Day 14 | 5500 ± 5982 | 2267 ± 933 | 8036 ± 3540 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4010 ± 1909 | 2891 ± 1099 | 7166 ± 4073 |
| Cycle 1, Day 14 | 6259 ± 7381 | 2074 ± 765 | 10082 ± 5421 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 176 ± 127 | 165 ± 63 | 495 ± 326 |
| Cycle 1, Day 14 | 552 ± 641 | 153 ± 78 | 866 ± 473 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cmin SU011248 | 29.0 ± 5.2 | 49.2 ± 13.0 | 30.2 ± 9.2 |
| Cmin SU012662 | 11.9 ± 9.3 | 18.7 ± 7.9 | 11.1 ± 2.6 |
| Cmin total drug (SU011248+SU012662) | 41.6 ± 15.6 | 68.5 ± 16.4 | 41.8 ± 11.3 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 24.8 ± 35.1 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cycle 1, Day 14 | 32.0 ± 45.2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 11.1 ± 15.7 | 13.0 ± 20.7 | 55.60 ± 100.9 |
| Cycle 1, Day 14 | 50.5 ± 71.4 | 0.00 ± 0.00 | 0.00 ± 0.00 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.0 ± 0.0 | 2.4 ± 7.1 | 34.4 ± 69.0 |
| Cycle 1, Day 14 | 33.5 ± 47.4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| ng/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.8 ± 2.5 |
| Cycle 1, Day 14 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| hour (hr) | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Tmax SU011248 | 4.0 (4.0 to 4.0) | 8.0 (2.0 to 10.0) | 8.0 (4.0 to 10.0) |
| Tmax SU012662 | 9.0 (8.0 to 10.0) | 8.0 (4.0 to 24.0) | 6.0 (0.0 to 10.0) |
| Tmax total drug (SU011248+SU012662) | 4.0 (4.0 to 4.0) | 8.0 (2.0 to 10.0) | 6.0 (4.0 to 10.0) |
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4.3 (0.5 to 8.0) | 2.0 (0.5 to 3.0) | 0.5 (0.3 to 4.0) |
| Cycle 1, Day 14 | 0.3 (0.3 to 0.3) | 2.0 (0.5 to 4.0) | 0.4 (0.0 to 3.0) |
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4.3 (0.5 to 8.0) | 2.0 (0.5 to 4.0) | 0.6 (0.5 to 4.0) |
| Cycle 1, Day 14 | 0.4 (0.3 to 0.5) | 3.0 (0.9 to 4.0) | 0.5 (0.0 to 3.0) |
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4.5 (1.0 to 8.0) | 2.0 (0.5 to 4.0) | 0.8 (0.5 to 4.0) |
| Cycle 1, Day 14 | 0.4 (0.3 to 0.5) | 3.0 (0.9 to 4.0) | 0.5 (0.0 to 3.0) |
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 4.5 (1.0 to 8.0) | 2.0 (0.5 to 4.0) | 0.6 (0.3 to 4.0) |
| Cycle 1, Day 14 | 0.4 (0.3 to 0.5) | 3.0 (0.5 to 4.0) | 0.5 (0.0 to 3.0) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
No measurements were reported for this outcome.
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.3 ± NA | 0.3 ± NA | 0.4 ± 0.11 |
| Cycle 1, Day 14 | 0.4 ± NA | 0.5 ± NA | 0.4 ± 0.12 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.7 ± NA | 1.0 ± 0.4 | 0.8 ± 0.2 |
| Cycle 1, Day 14 | 0.7 ± NA | 1.1 ± 0.7 | 0.8 ± 0.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.7 ± NA | 1.0 ± 0.4 | 0.7 ± 0.1 |
| Cycle 1, Day 14 | 0.6 ± NA | 1.0 ± 0.5 | 0.7 ± 0.1 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 0.8 ± NA | 1.2 ± 0.8 | 0.6 ± 0.1 |
| Cycle 1, Day 14 | 0.6 ± NA | 1.1 ± 0.4 | 0.6 ± 0.1 |
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state.
| nanogram hours per milliliter (ng*hr/mL) | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| AUC (0-24) SU011248 | 844 ± 155 | 1420 ± 379 | 902 ± 230 |
| AUC (0-24) SU012662 | 321 ± 254 | 524 ± 219 | 327 ± 64 |
| AUC (0-24) total drug (SU011248+SU012662) | 1163 ± 407 | 1944 ± 533 | 1230 ± 273 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| CAP (n = 1, 4, 10) | 7480 ± NA | 2828 ± 215 | 8069 ± 3877 |
| 5'DFCR (n = 1, 7, 10) | 9200 ± NA | 8853 ± 1648 | 11467 ± 2476 |
| 5'DFUR (n = 1, 6, 10) | 7770 ± NA | 5703 ± 1295 | 9099 ± 2288 |
| 5-FU (n = 1, 5, 9) | 386 ± NA | 285 ± 119 | 489 ± 190 |
AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12)
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| CAP (n = 1, 4, 9) | 25435 ± NA | 2663 ± 452 | 8865 ± 6533 |
| 5'DFCR (n = 1, 7, 10) | 15522 ± NA | 7087 ± 1222 | 10091 ± 2847 |
| 5'DFUR (n = 1, 6, 10) | 15522 ± NA | 4822 ± 1222 | 10291 ± 3675 |
| 5-FU (n = 1, 5, 10) | 1299 ± NA | 353 ± 141 | 842 ± 403 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 7555 ± 135 | 2899 ± 1580 | 7373 ± 4199 |
| Cycle 1, Day 14 | 13532 ± 16648 | 3157 ± 1171 | 8213 ± 6432 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 12815 ± 5494 | 8028 ± 1963 | 11229 ± 2516 |
| Cycle 1, Day 14 | 8614 ± 8477 | 6464 ± 1377 | 9776 ± 2868 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 8855 ± 1761 | 5658 ± 1237 | 8951 ± 2248 |
| Cycle 1, Day 14 | 8500 ± 9192 | 4829 ± 1015 | 10017 ± 3637 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*hr/mL | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|
| Cycle 1, Day 1 | 355 ± 27 | 291 ± 95 | 506 ± 200 |
| Cycle 1, Day 14 | 688 ± 802 | 350 ± 129 | 854 ± 390 |
Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| percentage of participants | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response | 16.7 (0.4 to 64.1) | 42.9 (9.9 to 81.6) | 46.7 (21.3 to 73.4) | 43.5 (23.2 to 65.5) | 0 (0.0 to 70.8) | 45.5 (24.4 to 67.8) |
DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first.
| months | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|
| Duration of Response (DR) | 14.1 (14.1 to 14.1) | 6.3 (6.0 to 10.9) | 10.5 (4.4 to 28.1) | 5.9 (2.8 to 12.8) | 6.3 (2.5 to 25.5) |
PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
| months | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) | 3.2 (2.7 to 9.3) | 6.6 (2.5 to 8.0) | 6.4 (4.3 to 13.9) | 8.0 (4.7 to 9.4) | 2.8 (2.3 to 11.7) | 5.5 (4.7 to 10.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | — | 1/6 (16.7%) | 6/6 (100%) |
| SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | — | 2/7 (28.6%) | 7/7 (100%) |
| SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | — | 8/15 (53.3%) | 15/15 (100%) |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | — | 8/23 (34.8%) | 23/23 (100%) |
| SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | — | 0/3 (0%) | 3/3 (100%) |
| SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | — | 5/22 (22.7%) | 22/22 (100%) |
| Event | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/6 | 0/7 | 1/15 | 0/23 | 0/3 | 0/22 |
| FatigueGeneral disorders | 1/6 | 0/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| CholecystitisHepatobiliary disorders | 1/6 | 0/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| Decreased appetiteMetabolism and nutrition disorders | 1/6 | 0/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/6 | 1/7 | 1/15 | 0/23 | 0/3 | 2/22 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/7 | 1/15 | 0/23 | 0/3 | 0/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/6 | 1/7 | 1/15 | 0/23 | 0/3 | 0/22 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| Sudden deathGeneral disorders | 0/6 | 1/7 | 0/15 | 0/23 | 0/3 | 0/22 |
| Event | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 5/6 | 6/7 | 15/15 | 18/23 | 2/3 | 18/22 |
| FatigueGeneral disorders | 6/6 | 6/7 | 5/15 | 9/23 | 1/3 | 8/22 |
| Decreased appetiteMetabolism and nutrition disorders | 5/6 | 6/7 | 11/15 | 15/23 | 3/3 | 13/22 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/6 | 6/7 | 10/15 | 16/23 | 2/3 | 8/22 |
| NauseaGastrointestinal disorders | 3/6 | 6/7 | 12/15 | 17/23 | 2/3 | 17/22 |
| StomatitisGastrointestinal disorders | 5/6 | 3/7 | 8/15 | 10/23 | 1/3 | 7/22 |
| AnaemiaBlood and lymphatic system disorders | 4/6 | 4/7 | 9/15 | 8/23 | 1/3 | 2/22 |
| Abdominal painGastrointestinal disorders | 4/6 | 4/7 | 7/15 | 6/23 | 1/3 | 10/22 |
| ConstipationGastrointestinal disorders | 4/6 | 3/7 | 7/15 | 8/23 | 0/3 | 5/22 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/6 | 0/7 | 1/15 | 5/23 | 2/3 | 2/22 |
| Age Continuous(years) | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 55.2 ± 5.8 | 50.0 ± 12.4 | 50.9 ± 11.3 | 54.3 ± 10.1 | 63.3 ± 11.6 | 50.1 ± 11.5 | 52.4 ± 10.9 |
| Sex: Female, Male(Participants) | SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2 | SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 2 | 6 | 6 | 1 | 8 | 23 |
| Male | 6 | 5 | 9 | 17 | 2 | 14 | 53 |
The record gives a start of May 2008, a primary completion of Aug 2010 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxaliplatin · Cisplatin